Kapiva Valuation, Funding & Investors
Kapiva is valued at $80M as of September 2024.
Last Kapiva valuation
$80M
Series C · Sep 2024
Last Kapiva funding round
$32M
Series D · Sep 2025
Cumulative funding Kapiva raised
$86M
across 6 funding rounds
Key investors in Kapiva
3one4 Capital
Vertex Ventures
OrbiMed
Vertex Ventures Southeast Asia & India
360 ONE Asset
Vertex Growth Fund
About Kapiva
Kapiva is a Mumbai-headquartered wellness firm fusing Ayurveda principles with scientific validation for natural remedies. It manufactures over 200 GMP-certified products like Amla juice shots, Ashwagandha supplements, turmeric ghee, and hair oils targeting digestion, immunity boosting, stress relief, hypertension control, and skincare sourced from Himalayan farms.
Founded
2016
HQ
BangaloreWebsite
Status
Privately held
Customer focus
B2C
Revenue model
Product sales
Valuation
$80M (Sep 2024)
Kapiva Valuation
Kapiva is currently valued at $80M, based on its Series C in September 2024.
The $10M round was led by OrbiMed, with participation from Vertex Ventures and 3one4 Capital.
Kapiva valuation by funding round
| Date | Stage | Valuation |
|---|---|---|
| Sep 2024 | Series C | $80M |
Kapiva Funding History
Kapiva has raised a total of $86M across 6 funding rounds, plus 1 secondary share sale.
Kapiva's first fundraising round was a $3M Series A in January 2019. The most recent completed round was a $32M Series D in September 2025.
Kapiva funding rounds
| Date | Stage | Investors | Raised | Valuation | Deal Summary |
|---|---|---|---|---|---|
| Sep 2025 | Series D | 360 ONE Asset (lead); Vertex Growth Fund (lead); Vertex Ventures Southeast Asia & India; 3one4 Capital | $32M | - | Kapiva is a Bengaluru-based modern Ayurveda brand specializing in evidence-based products for diabetes, hypertension, energy, liver function, sports, nutrition, and heart health, integrating scientific validation with traditional formulations. The company operates an omnichannel model through its direct-to-consumer website, marketplaces, quick commerce apps (contributing 10% of revenue), and over 40,000 offline stores in India, aiming to expand to 100,000 stores within a year. It has recently gone global with subsidiaries in the US (Kapiva Inc.), UAE, and UK, which account for 5-10% of overall revenue. On September 29, 2025, Kapiva raised over $60 million (Rs 510 crore) in a Series D round led by 360 ONE Asset and Vertex Growth Fund, with participation from existing investors Vertex Ventures Southeast Asia & India and 3one4 Capital. The round comprised $28 million (Rs 240 crore) in primary capital for R&D, manufacturing, brand building, and health-tech ecosystem development, and $32 million in secondary sales enabling an exit for early investor Fireside Ventures. Avendus Capital served as the exclusive financial advisor; this pre-IPO raise positions the company for an IPO in 2-3 years. Kapiva reported a strong annual revenue run rate (ARR) of Rs 550 crore at the time of the round, up from Rs 350 crore in FY25, with over 80% year-on-year growth for the past three years. It is currently single-digit EBITDA negative but approaching breakeven, expecting to turn positive the following quarter. The Indian nutraceuticals and nutrition market is estimated at nearly $10 billion, growing 7-8% annually, where Kapiva differentiates through its research-led, consumer-trusted positioning targeting millennials and Gen Z. |
| Sep 2025 | Secondary | 360 ONE Asset (lead); Vertex Growth Fund (lead); Vertex Ventures Southeast Asia & India; 3one4 Capital | $32M | - | Kapiva is a Bengaluru-based modern Ayurveda brand offering products for diabetes, energy, sports, nutrition, liver, and heart health, sold through its direct-to-consumer website, marketplaces, offline stores, and quick commerce apps. It operates in over 40,000 stores in India and has expanded globally with subsidiaries in the US, UAE, and UK, which contribute 5-10% to overall revenue. On September 29, 2025, Kapiva raised over $60 million (Rs 510 crore) in a Series D funding round led by 360 ONE Asset and Vertex Growth Fund, with participation from existing investors Vertex Ventures Southeast Asia & India and 3one4 Capital. The round included $28 million (Rs 240 crore) in primary capital for R&D, manufacturing, brand building, and health-tech ecosystem development, and $32 million in secondary sales enabling an exit for early investor Fireside Ventures, advised by Avendus Capital. Kapiva achieved an annual revenue run rate of Rs 550 crore, up from Rs 350 crore in FY25, with over 80% year-on-year growth for the past three years; it is single digit EBITDA negative and nearing breakeven. |
| Sep 2024 | Series C | OrbiMed (lead); Vertex Ventures; 3one4 Capital | $10M | $80M | Kapiva is a Bengaluru-based modern Ayurveda wellness brand founded in 2015 by Ameve Sharma and Shrey Badhani, offering natural and organic products for diabetes, hypertension, liver health, hormonal balance, energy, sports nutrition, and overall wellness. The company distributes through its website, ecommerce marketplaces, offline retail in 40,000 stores across India, and has expanded globally to the Middle East, Europe, and North America via a US subsidiary. In September 2024, Kapiva initiated its funding with a Series C round of USD 10 million (INR 83.5 crore) led by OrbiMed, with participation from Vertex Ventures and 3one4 Capital, at a valuation of USD 80 million to support growth and market expansion. This preceded a larger Series D round in 2025 raising over USD 60 million (INR 510 crore), including USD 28 million primary capital led by 360 ONE Asset and Vertex Growth, with Vertex Ventures and 3one4 Capital participating, and secondary sales enabling Fireside Ventures' exit. Kapiva achieved over 80% year-on-year growth for three years, reaching an annual revenue run rate (ARR) exceeding INR 550 crore, with top categories like diabetes, gym supplements, energy, heart, and liver comprising 96-97% of revenue. Funds from the rounds support R&D, manufacturing, brand building, health-tech platform, and international expansion, positioning Kapiva in the shift toward preventive healthcare with science-backed Ayurveda. |
| Sep 2022 | Series C | 3one4 Capital (lead); OrbiMed (lead); Vertex Ventures (lead) | $28M | - | Kapiva's Series D funding round closed in September 2025, which raised USD 60 million (INR 510 crores) including USD 28 million in primary capital, led by 360 ONE Asset and Vertex Growth. As of September 2025, Kapiva reported an annual revenue run rate of over INR 550 crores with over 80% year-on-year growth achieved over the preceding three years. The company employed over 500 people and operated across 40,000 retail touchpoints. For the fiscal year ending March 2025, Kapiva reported revenues of INR 342 crore (50% growth from INR 228 crore in FY24) but faced widening losses of INR 69 crore due to escalating advertising and operational expenses. |
| Jan 2021 | Series B | Vertex Ventures | $11M | - | Kapiva raised USD 11 million in its Series B funding round in January 2021, with participation from Vertex Ventures, 3one4 Capital, Fireside Ventures, and Jetty Ventures. The funds were intended to support product development and geographical expansion. This followed a Series A round of USD 2.5 million in 2019 led by Fireside Ventures with 3one4 Capital, Mohandas Pai’s Family Office, Madhu Kela, and Gits Foods. |
| Apr 2020 | Series A | Jetty Ventures | $2M | - | - |
| Jan 2019 | Series A | Fireside Ventures (lead); Madhu Kela | $3M | - | Kapiva raised $2.5 million in a Series A funding round in January 2019 led by Fireside Ventures. The funds were used to scale operations and expand product offerings. Fireside Ventures later fully exited in a 2025 Series D round. Kapiva is an Ayurvedic wellness brand founded in 2016 by Ameve Sharma, from the Baidyanath Group family, and Shrey Badhani, a former Bain & Co consultant. The company offers products in categories like diabetes care, sports nutrition, liver function, and general wellness, sold via e-commerce, its website, and 40,000 retail outlets in India, with expansion to the US, Middle East, and Europe. Subsequent rounds included $10 million in Series C in September 2024 at $80 million valuation, $28 million primary in Series D in September 2025 led by 360 ONE Asset and Vertex Growth Fund, and a $60 million round combining primary and secondary capital providing liquidity to early investors. |
Who has invested in Kapiva?
9 investors have backed Kapiva across its funding rounds, including 3one4 Capital, Vertex Ventures, OrbiMed, Vertex Ventures Southeast Asia & India, 360 ONE Asset and Vertex Growth Fund.
Lead investors include 360 ONE Asset, Vertex Growth Fund, OrbiMed, 3one4 Capital, Vertex Ventures and 1 other investor.
Kapiva Investors
| Investor | HQ | Rounds | Role | First check |
|---|---|---|---|---|
| India | 4 | Lead | Sep 2022 | |
 Singapore | 3 | Lead | Jan 2021 | |
| Singapore | 2 | Participant | Sep 2025 | |
| India | 2 | Lead | Sep 2025 | |
 New York City, NY | 2 | Lead | Sep 2022 | |
| Singapore | 2 | Lead | Sep 2025 | |
| Bangalore | 1 | Lead | Jan 2019 | |
This data is available for Pro users. Sign up to see all 9 Kapiva investors. Start Free Trial | ||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialKapiva Competitors
Kapiva competitors include listed companies like FitLife Brands and Chong Kun Dang Holdings, and private ones like Heights, Kaffe Bueno, Dilan Biotech and Nutrables.
| Company | HQ | Status | Revenue | EBITDA | Valuation | Revenue Multiple |
|---|---|---|---|---|---|---|
 London | Private | - | - | $78M | - | |
| United States | Publicly listed | $81M | $10M | $90M | 1.3x | |
 Copenhagen | Private | - | - | $59M | - | |
![](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="20" height="20" viewBox="0 0 20 20"><rect fill="%23e5e7eb" width="20" height="20" rx="4"/></svg>){kind=small} Dilan Biotech |  Nanan | Private | - | - | $110M | - |
| Phoenix, AZ | Private | - | - | $56M | - | |
 South Korea | Publicly listed | $698M | $94M | $132M | - |
Kapiva Public Comps
Kapiva is still privately-owned, but its public comps include Hyundai Bioland Co, Hofseth BioCare, SkinHealth Systems, FitLife Brands, Biome Australia, Lamasat, Promopharm, Comvita, Suominen and Solesence.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $95M | $12M | 0.8x | - | 6.0x | - | |||
| $27M | ($8M) | 3.5x | - | (12.1x) | - | |||
| $301M | $30M | 0.8x | - | 8.4x | - | |||
| $81M | $10M | 1.6x | 1.3x | 12.2x | 8.5x | |||
| $13M | $413K | 5.3x | 3.7x | 167.7x | 44.0x | |||
| $39M | $13M | 2.3x | - | 7.1x | - | |||
| $103M | $12M | 0.9x | - | 7.4x | - | |||
| $122M | $13M | 0.6x | 0.6x | 5.4x | 5.1x | |||
This data is available for Pro users. Sign up to see all Kapiva competitors and their valuation data. Start Free Trial | ||||||||
Common questions about Kapiva
| When was Kapiva founded? | Kapiva was founded in 2016. |
| Where is Kapiva headquartered? | Kapiva is headquartered in Bangalore, India. |
| Is Kapiva publicly listed? | No, Kapiva is a private, VC-backed company. |
| What is Kapiva's valuation? | Kapiva was last valued at $80M in its Series C in September 2024. |
| How much funding has Kapiva raised? | Kapiva has raised $86M across 6 funding rounds. |
| What was Kapiva's last funding round? | Kapiva's last funding round was a $32M Series D in September 2025, led by 360 ONE Asset and Vertex Growth Fund. |
| Who are Kapiva's investors? | Kapiva's investors include 3one4 Capital, Vertex Ventures, Vertex Ventures Southeast Asia & India, 360 ONE Asset, OrbiMed, Vertex Growth Fund, Fireside Ventures, Jetty Ventures and Madhu Kela. |
| Which companies are comparable to Kapiva? | Companies comparable to Kapiva include Heights, FitLife Brands, Kaffe Bueno, Dilan Biotech, Nutrables and Chong Kun Dang Holdings. |
See companies similar to Kapiva
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.